Clinical Trial Search

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Assessing Percentage of Participants Who Reported Adverse Events Following Treatment by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 — 4.1; 4.3; 4.1; 10…

Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants

Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…

Primary: All Cause Mortality — 171; 183 Participants

Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40

Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL

Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants

Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031

Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants

Primary: PET Biomarker Uptake — 0.95; 0.98 Standard Uptake Measure SUV

Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2

Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…

Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants

Primary: Overall Time to Disease Progression — 10.9; 9.9 Weeks — p=0.719

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants

Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants

Primary: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort) — 1; 1; 1; 1 Participants

Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc

Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants

Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190

Primary: Sensitivity and Specificity of High Resolution Versus Standard MRI in Identifying Adverse Histology — 75; 71; 84; 54.8 percent

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Percentage of Participants With PSA50 Response — 2 Participants